[{"data":1,"prerenderedAt":170},["ShallowReactive",2],{"drug-saxagliptin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":68,"warnings":78,"renal":86,"monitoring":96,"interactions":97,"review":98,"examples":101,"atc":107,"iran":109,"usApproval":116,"links":122,"populations":136},"saxagliptin",1,{"fa":7,"en":8},"ساکساگلیپتین","Saxagliptin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده DPP-4","DPP-4 inhibitor",[14],{"name":15,"market":16},"Onglyza","US",[18,19,7],"onglyza","انگلیزا",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-5","tablet","oral","5 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},5,"mg",false,[16],[32],{"source":33,"section":34},"fda-saxagliptin","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-2-5","2.5 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},2.5,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56,"notes":59},"t2dm","type-2-diabetes",{"fa":48,"en":49},"دیابت نوع ۲ بزرگسال — ۲٫۵ یا ۵ mg یک بار","Type 2 diabetes, adults — 2.5 or 5 mg once daily",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":39,"perDoseMax":27,"dosesPerDay":5},[57],{"source":33,"section":58},"2.1",[60],{"text":61,"refs":64},{"fa":62,"en":63},"با مهارکننده قوی CYP3A4\u002F5 حداکثر ۲٫۵ mg. قرص خرد یا جویده نشود.","With strong CYP3A4\u002F5 inhibitors max 2.5 mg. Do not cut, crush or chew.",[65,67],{"source":33,"section":66},"2.3",{"source":33,"section":58},[69],{"id":70,"severity":71,"text":72,"refs":75},"hyper","block",{"fa":73,"en":74},"سابقه حساسیت جدی به ساکساگلیپتین (آنافیلاکسی، آنژیوادم، ضایعات پوستی اکسفولیاتیو).","History of serious hypersensitivity to saxagliptin (anaphylaxis, angioedema, exfoliative skin conditions).",[76],{"source":33,"section":77},"4",[79],{"text":80,"refs":83},{"fa":81,"en":82},"پانکراتیت؛ نارسایی قلب؛ هیپوگلیسمی با انسولین یا سولفونیل‌اوره؛ واکنش حساسیتی؛ درد مفصلی شدید؛ پمفیگوئید بولوز.","Pancreatitis; heart failure; hypoglycaemia with insulin or sulfonylureas; hypersensitivity; severe arthralgia; bullous pemphigoid.",[84],{"source":33,"section":85},"5",[87],{"egfrBelow":88,"severity":89,"text":90,"refs":93},45,"warn",{"fa":91,"en":92},"eGFR زیر ۴۵: ۲٫۵ mg یک بار.","eGFR \u003C45: 2.5 mg once daily.",[94],{"source":33,"section":95},"2.2",[],[],{"status":99,"reviewer":100,"date":100},"unverified",null,[102],{"regimen":45,"formulation":36,"input":103,"expect":106},{"ageYears":104,"weightKg":105},55,80,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":27},[108],"A10BH03",{"status":110,"refs":111},"not-found",[112],{"source":113,"section":114,"url":115},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Saxagliptin",{"kind":117,"refs":118,"id":121},"ANDA",[119],{"source":33,"section":120},"SPL approval \u002F marketing category","ANDA205994",[123,126,130,133],{"kind":124,"url":125,"label":121},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=205994",{"kind":127,"url":128,"label":129},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e286ffd4-c598-47fb-af06-2e15f7e6f99f","FDA Saxagliptin",{"kind":131,"url":132,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa610003.html",{"kind":134,"url":135,"label":108},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BH03",{"pregnancy":137,"lactation":146,"pediatric":154,"geriatric":162},{"level":138,"text":139,"quote":142,"refs":143},"caution",{"fa":140,"en":141},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data with saxagliptin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriages.",[144],{"source":33,"section":145},"8.1",{"level":138,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of saxagliptin in human milk, the effects on the breastfed infant, or the effects on milk production.",[152],{"source":33,"section":153},"8.2",{"level":138,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of saxagliptin as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus have not been established. in pediatric patients..",[160],{"source":33,"section":161},"8.4",{"level":138,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function [ see Dosage and Administration (2.2)and Clinical Pharmacology (12.3) ].",[168],{"source":33,"section":169},"8.5",1792444422295]